ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

ClinicalTrials.gov ID: NCT06169215

Public ClinicalTrials.gov record NCT06169215. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma

Study identification

NCT ID
NCT06169215
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
70 participants

Conditions and interventions

Interventions

  • Biospecimen Collection Procedure
  • Bone Marrow Aspiration Procedure
  • Bone Marrow Biopsy Procedure
  • Bortezomib Drug
  • Computed Tomography Procedure
  • Daratumumab and Recombinant Human Hyaluronidase Drug
  • Dexamethasone Drug
  • Lenalidomide Drug
  • Magnetic Resonance Imaging Procedure
  • Positron Emission Tomography Procedure
  • Selinexor Drug

Procedure · Drug

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 22, 2024
Primary completion
Sep 29, 2026
Completion
Sep 29, 2026
Last update posted
Apr 12, 2026

2024 – 2026

United States locations

U.S. sites
27
U.S. states
8
U.S. cities
25
Facility City State ZIP Site status
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine California 92612
UCI Health Laguna Hills Laguna Hills California 92653
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California 92868
University of California Davis Comprehensive Cancer Center Sacramento California 95817
Smilow Cancer Hospital-Derby Care Center Derby Connecticut 06418
Smilow Cancer Hospital Care Center-Fairfield Fairfield Connecticut 06824
Smilow Cancer Hospital Care Center at Glastonbury Glastonbury Connecticut 06033
Smilow Cancer Hospital Care Center at Greenwich Greenwich Connecticut 06830
Smilow Cancer Hospital Care Center - Guilford Guilford Connecticut 06437
Smilow Cancer Hospital Care Center at Saint Francis Hartford Connecticut 06105
Smilow Cancer Center/Yale-New Haven Hospital New Haven Connecticut 06510
Yale University New Haven Connecticut 06520
Yale-New Haven Hospital North Haven Medical Center North Haven Connecticut 06473
Smilow Cancer Hospital Care Center at Long Ridge Stamford Connecticut 06902
Smilow Cancer Hospital-Torrington Care Center Torrington Connecticut 06790
Smilow Cancer Hospital Care Center-Trumbull Trumbull Connecticut 06611
Smilow Cancer Hospital-Waterbury Care Center Waterbury Connecticut 06708
Smilow Cancer Hospital Care Center - Waterford Waterford Connecticut 06385
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287
NYU Langone Hospital - Brooklyn Brooklyn New York 11220
NYU Langone Hospital - Long Island Mineola New York 11501
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York 10016
NYP/Weill Cornell Medical Center New York New York 10065
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Smilow Cancer Hospital Care Center - Westerly Westerly Rhode Island 02891
Vanderbilt University/Ingram Cancer Center Nashville Tennessee 37232
VCU Massey Comprehensive Cancer Center Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06169215, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06169215 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →